Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954706 | 0.82 | ALDH1A1 (0.34) | MAPTKIF11TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL9004920 | 0.81 | KDM4E (0.43) | NPSR1KIF11SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5547736 | 0.80 | SMN1; SMN2 (0.33) | L3MBTL1MAPTCFTRLMNAPDE2A | |
| SCHEMBL5054248 | 0.80 | TSHR (0.34) | TSHR | |
| SCHEMBL1068587 | 0.80 | CES2 (0.32) | L3MBTL1MAPTMAPK1CFTRPDE2A | |
| SCHEMBL6226618 | 0.79 | L3MBTL1 (0.41) | L3MBTL1MAPTMAPK1LMNANPSR1 | |
| SCHEMBL15352508 | 0.79 | PDE2A (0.38) | MAPTLMNANPSR1PDE2AKIF11 | |
| SCHEMBL8135398 | 0.78 | CYP11B1 (0.31) | — | |
| SCHEMBL160634 | 0.77 | MAPT (0.36) | L3MBTL1MAPTMAPK1PDE2ATSHR | |
| SCHEMBL1066344 | 0.77 | MEN1 (0.35) | MAPTMAPK1LMNANPSR1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932609-B1 | Substituted 1,4-dihydropyrimidines as antitubercular agents | King Faisal University (SA) | 2024-03-19 | — | — | US | claimed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | claimed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| EP-3348547-B1 | BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-07-22 | — | — | EP | claimed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | claimed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| CN-110612296-A | Phenyl derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | claimed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | claimed |
| EP-1383498-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | claimed |
| WO-2003008412-A2 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-01-30 | — | — | WO | claimed |
| WO-2003008414-A1 | CHEMICAL COMPOUNDS | SB PHARMCO PUERTO RICO INC. (PR) | 2003-01-30 | — | — | WO | claimed |
| WO-2002100863-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| WO-2002087573-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | claimed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | claimed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | claimed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | L3MBTL1 4109/4885RAB9A 4075/4885MAPT 4435/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | L3MBTL1 4017/4885RAB9A 4040/4885MAPT 4397/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885RAB9A 1917/4885MAPT 268/4885 |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | L3MBTL1 2411/4885RAB9A 3042/4885MAPT 4215/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885RAB9A 1917/4885MAPT 268/4885 |
| US-11932609-B1 | Substituted 1,4-dihydropyrimidines as antitubercular agents | DPYD, DUT, TYMP | L3MBTL1 1587/4885RAB9A 2769/4885MAPT 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.